Treatment with any other investigational agent within 4 weeks (or within five half-lives of the investigational product, whichever is shorter) prior to cycle 1, day 1 (minimum of 1 week between prior therapy and study enrollment); patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (also referred to as an “early phase I study” or “pre-phase I study” where a sub-therapeutic dose of drug is administered) at the coordinating center PI’s discretion, and should have recovered to eligibility levels from any toxicitiesXx_NEWLINE_xXMust not have received investigational therapy within 30 days of entry onto this studyXx_NEWLINE_xXCurrent or past participation in a study of an investigational agent or using an investigational device within four weeks of registration for protocol therapyXx_NEWLINE_xXParticipants should not have received any other investigational agents nor have participated in an investigational trial within the past 4 weeksXx_NEWLINE_xXInvestigational drugs: Patients who are currently receiving another investigational drug are not eligibleXx_NEWLINE_xXPatients who are currently participating in or have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXThe patient has received any investigational therapy within 4 weeks of enrollmentXx_NEWLINE_xXThe use of any investigational medication or device in the 30 days prior to screening and throughout the study is prohibited.Xx_NEWLINE_xXNo treatment with any other type of investigational agent =< 4 weeks before pre-registrationXx_NEWLINE_xXPatients must NOT receive concurrent anti-cancer therapy or investigational agent unless specified in protocolXx_NEWLINE_xXPatients who are receiving any other investigational agent(s)Xx_NEWLINE_xXNo investigational agent within 21 days prior to registrationXx_NEWLINE_xXTreatment with any other investigational agent within 4 weeks prior to randomizationXx_NEWLINE_xXReceiving any other investigational agent that would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXConcurrent therapy with other Investigational Products.Xx_NEWLINE_xXParticipants who are currently receiving any other investigational agents; treatment with an investigational agent within 2 weeks prior to planned initiation of study therapy is allowed provided that any drug-related toxicity has completely resolvedXx_NEWLINE_xXAny prior treatment with any investigational drug within the preceding 4 weeksXx_NEWLINE_xXSubject has received other investigational therapy within the last 28 days.Xx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXTreatment with another investigational agent under the following conditions:Xx_NEWLINE_xXConcomitant treatment with another investigational agent while participating this trial.Xx_NEWLINE_xXPatients who are receiving any other concurrent investigational therapy, or who have received investigational therapy within 30 days of the first scheduled day of protocol treatment (investigational therapy as defined as treatment for which there is currently no regulatory authority approved indication) will not be eligibleXx_NEWLINE_xXUse of an investigational agent or an investigational device within 21 days before administration of first dose of study drug(s).Xx_NEWLINE_xXBiologic or investigational agent (anti-neoplastic): patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent >= 7 days prior to study enrollment\r\n* For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occurXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of first dose of treatment.Xx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXUse of any investigational drug within the past 4 weeksXx_NEWLINE_xXPrior treatment with any investigational drug within the preceding 2 weeksXx_NEWLINE_xXParticipants cannot have been treated on a prior interventional, investigational study within 2 weeks of the first dose of study treatmentXx_NEWLINE_xXTreatment with any investigational agent within 28 days prior to registration for protocol therapyXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.Xx_NEWLINE_xXNo chemotherapy, other investigational agents within 14 days of study treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPrior participation in an investigational study (drug, procedure or device) within 21 days of study day 1.Xx_NEWLINE_xXPatients should have been off other investigational therapy for one month prior to receiving treatment on this studyXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXInvestigational treatment - 4 weeksXx_NEWLINE_xXUse of an investigational agent or an investigational device within 28 days before administration of first dose of study drug(s).Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatients who are currently receiving any other investigational agentXx_NEWLINE_xXTreatment with investigational therapy within 30 days prior to initiation of study treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXTreatment with an investigational agent within 4 weeks of the first dose of treatmentXx_NEWLINE_xXThe subject has received another investigational agent within 21 days of the first dose of study drugXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device =< 28 days prior to registrationXx_NEWLINE_xXParticipation in an interventional, investigational study within 2 weeks of the first dose of study treatment.Xx_NEWLINE_xXPatient is currently receiving or has received another investigational agent within 4 weeks prior to day 1 of studyXx_NEWLINE_xXSubject is enrolled (concurrently) in another investigational study, with the exception of the follow-up period of another investigational study in which no anti-cancer therapy is being administered and where only data are being collected;Xx_NEWLINE_xXCOHORT 1: Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment\r\n* NOTE: Subjects who were treated on a clinical study of allogeneic stem cell transplant (alloHSCT) will be eligible if they are at least 3 months after allogeneic HCT and are at least 3 weeks (>21 days) off of all immune suppression and have no evidence of active GVHD (physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is allowed). Subjects with prior alloHSCT will not be eligible for enrollment during the safety run in phaseXx_NEWLINE_xXCOHORT 2: Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment for pre-existent myeloid disorder such as MDS or MPNXx_NEWLINE_xXPatients who are currently receiving another investigational agent are excludedXx_NEWLINE_xXSAFETY RUN-IN: Patients participating in another trial of an investigational agent within 4 weeks of the first dose of the studyXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.Xx_NEWLINE_xXOther investigational treatment during or within 30 days before starting study registrationXx_NEWLINE_xXConcurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks prior to study registrationXx_NEWLINE_xXCurrent or planned participation in a study of an investigational agent or using an investigational deviceXx_NEWLINE_xXAdministration of an investigational drug in the 28 days before the first dose of study treatmentXx_NEWLINE_xXConcurrent therapy with any other investigational drugXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXCurrently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study medicationXx_NEWLINE_xXPrior treatment with any investigational drug within the preceding 2 weeksXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXOther investigational agent(s) within 21 days prior starting to study treatment.Xx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, any ancillary therapy considered investigational (utilized for a non-FDA-approved indication and in the context of a research investigation) or receiving any other investigational agent which would be considered as a treatment for the primary neoplasm.Xx_NEWLINE_xXExposure to any other investigational agent at any time within 4 weeks before the first dose of study treatmentXx_NEWLINE_xXPatients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosingXx_NEWLINE_xXCurrently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study drugXx_NEWLINE_xXPatients may not be receiving any other investigational agentXx_NEWLINE_xXTreatment with any investigational agent within 4 weeks prior to baselineXx_NEWLINE_xXTREATMENT: Patients should have been off other investigational therapy for one month prior to entry in this studyXx_NEWLINE_xXPatients must not have received an investigational drug within 14 daysXx_NEWLINE_xXPatients should have been off other investigational therapy for one month prior to entry in this studyXx_NEWLINE_xXThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXCurrent enrollment in any other investigational treatment studyXx_NEWLINE_xXIs currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of trial treatment.Xx_NEWLINE_xXParticipation in a study of an investigational agent or device within 4 weeks of DayXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study therapyXx_NEWLINE_xXCurrently receiving any other investigational agent or received an investigational agent within last 30 days of study entry.Xx_NEWLINE_xXCurrently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study therapyXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.Xx_NEWLINE_xXUse of any investigational agent within 28 days prior to randomization.Xx_NEWLINE_xXTreatment with investigational therapy within 14 days prior to initiation of study treatmentXx_NEWLINE_xXParticipation in any study involving administration of an investigational agent within 30 days of randomization into this studyXx_NEWLINE_xXParticipants may not be receiving treatment with any investigational drug or biologic within 30 days of randomization or at any time during the study.Xx_NEWLINE_xXReceived another investigational agent within 30 days of enrollmentXx_NEWLINE_xXPrior participant in another protocol using an investigational agent within 5 half-lives of the investigational agentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of study registrationXx_NEWLINE_xXPatients should have been off other investigational therapy for one month prior to receiving treatment on this studyXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks or 5 half-lives of the first dose of treatment, whichever is shorterXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXReceived an investigational agent for any indication within 30 days prior to first treatment.Xx_NEWLINE_xXHas participated in a study of an investigational agent and has received study therapy or has used an investigational device within 28 days of administration of MK-1454.Xx_NEWLINE_xXTreatment with any therapeutic investigational agent within 28 days prior to study registration.Xx_NEWLINE_xXThe participant has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXUse of investigational agent within 28 days prior to randomizationXx_NEWLINE_xXParticipated in another investigational study (drug or device) within 4 weeks of first doseXx_NEWLINE_xXPatients who are receiving any other investigational or chemotherapeutic agents will be excluded; please contact the study principal investigator (PI) if a patient has received an investigational or chemotherapeutic agent in the pastXx_NEWLINE_xXCurrently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study medicationXx_NEWLINE_xXCurrently participating and receiving study therapy in, or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the date of allocation/randomizationXx_NEWLINE_xXPrior systemic anti-cancer therapy including investigational agent within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agentXx_NEWLINE_xXInvestigational Drugs\r\n* Patients who are currently receiving another investigational drug are not eligible\r\n* Prior treatment with another investigational drugXx_NEWLINE_xXTreatment with any investigational products within 2 weeks before administration of the first dose of the study drugs.Xx_NEWLINE_xXPatients who have received treatment with an investigational drug within 30 days preceding the first dose of study medicationXx_NEWLINE_xXParticipants is taking another investigational agentXx_NEWLINE_xXTreatment within 30 days prior to randomization with another investigational device or drug study (ies).Xx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXTreatment with any investigational agent or approved therapy within 28 daysXx_NEWLINE_xXReceiving an investigational GVHD treatment within 28 days of study entry.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to administration of pembrolizumab.Xx_NEWLINE_xXPatient is currently receiving or has received another investigational agent within 4 weeks prior to study day 1Xx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceived any other investigational agent or systemic cytotoxic chemotherapy within the preceding 2 weeksXx_NEWLINE_xXReceived an investigational agent within 30 days prior to starting study treatmentXx_NEWLINE_xXCurrently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated and received study therapy in a study of an investigational agent, or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatients who are receiving concurrent investigational therapy or who have received investigational therapy within a period of 5 half-lives of the investigational therapy in question prior to the day of dosing with the PEGylated AuroShell particles (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)Xx_NEWLINE_xXThe patient has previously received treatment with SL-801 or another investigational agent that inhibits the XPO1/CRM1 pathway.Xx_NEWLINE_xXReceiving other investigational agent concomitantlyXx_NEWLINE_xXThe patient has received an investigational drug within 30 days of the first dose of study drug.Xx_NEWLINE_xXCurrent enrollment in another clinical study involving treatment and/or is receiving an investigational agent for any reason, or use of any investigational agents within 14 days of initiating study treatment.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXInvestigational Drugs: Subjects who have received another investigational drug within the last 14 days are excluded from participation.Xx_NEWLINE_xXTreatment with any investigational drug 30 days prior to randomizationXx_NEWLINE_xXPrior participation in an investigational study within 21 days of study day 1Xx_NEWLINE_xXOther investigational therapy: at least two weeks since any other investigational therapyXx_NEWLINE_xXSubject has received treatment with any investigational immunotherapy within 2 years prior to study screening or has received treatment with any other investigational product within 28 days prior to study screeningXx_NEWLINE_xXConcurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 2 weeks of trial entry (signing of the informed consent form)Xx_NEWLINE_xXTreatment with an investigational agent within 4 weeks of registrationXx_NEWLINE_xXConcurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)Xx_NEWLINE_xXPatients are not eligible if they are using any other approved or investigational anti-neoplastic therapies or any other investigational therapies for any other reason.Xx_NEWLINE_xXSubject who has been treated with an investigational product and has not completed the entire follow-up period for that investigational product;Xx_NEWLINE_xXInvestigational therapy within 28 days prior to initiation of study treatmentXx_NEWLINE_xXCurrently participating in or has participated in a study of an investigational agent or using an investigational device =< 28 days prior to registrationXx_NEWLINE_xXReceiving any other investigational agent that would be considered as a treatment for the lymphomaXx_NEWLINE_xXPatients who had therapy with one of the investigational agents more than 1 month prior to enrollment in whom tumor genotyping show assignment to the same investigational agentXx_NEWLINE_xXTreatment with any investigational products within 30 days before randomization.Xx_NEWLINE_xXCurrently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device within 3 weeks of the first dose of MK-3475Xx_NEWLINE_xXCurrently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of MK-3475Xx_NEWLINE_xXTreatment with any investigational products within 14 days before the first dose of study drugXx_NEWLINE_xXPatients should have been off other investigational therapy for one month prior to entry in this studyXx_NEWLINE_xXPatients who are currently receiving another investigational agent are excludedXx_NEWLINE_xXAny other investigational drug within 30 days prior to registration and during the studyXx_NEWLINE_xXPrior treatment with any investigational drug within the preceding 4 weeksXx_NEWLINE_xXPlans to initiate treatment with an investigational agent during the studyXx_NEWLINE_xXoff other investigational therapy for one month prior to entry in this study.Xx_NEWLINE_xXHave taken an investigational agent within 30 days of visit 1Xx_NEWLINE_xXParticipation in any other research protocol involving administration of an investigational agent within 1 month prior to study entryXx_NEWLINE_xXParticipation in any investigational drug study within 4 weeks preceding enrollmentXx_NEWLINE_xXUse of any standard chemotherapy or other investigational agent(s) within 1 week of study enrollmentXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXHas received an investigational therapy within 30 days of first dose of study drugXx_NEWLINE_xXPatients who have received any chemotherapy or investigational treatment within 4 weeks of study startXx_NEWLINE_xXHas received treatment with any investigational drug in the previous 4 weeksXx_NEWLINE_xXCurrently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of first dose of treatment or used an investigational device within 4 weeks of the first dose of treatment.Xx_NEWLINE_xXEXCLUSION - PARTICIPANT: Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks of first dose of treatment. \r\n* Individuals in the follow-up phase of a prior investigational study may participate as long as it has been 4 weeks since last dose of the previous investigational agent of device.Xx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or an investigational device within 4 weeks of the first dose of treatment.Xx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXTreatment with any investigational compound within 30 days prior to the first dose of study drugsXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment\r\n* Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agentXx_NEWLINE_xXTreatment with an investigational drug study within 28 days of before starting on study treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 2 weeks of the first dose of treatmentXx_NEWLINE_xXPatients receiving investigational agent within 30 days of enrollment. However, the principal investigator (PI) may approve prior use of an investigational agent if the agent is not expected to interfere with the safety or the efficacy of alpha-1-antitrypsin.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXThe patient has received any investigational drug within the past 4 weeksXx_NEWLINE_xXTreatment with any investigational drug within 30 days prior to registration.Xx_NEWLINE_xXTaken an investigational drug within 4 weeks prior to study drug administration or plans to take an investigational agent during the studyXx_NEWLINE_xXAdministration of an investigational therapeutic within 30 days of treatment startXx_NEWLINE_xXParticipants must not be currently receiving study therapy or have participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXTreatment with any investigational products within 4 weeks before the first dose of study drug.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXAny investigational drug within 28 days prior to study treatment.Xx_NEWLINE_xXCurrent or planned participation in a study of another investigational agent or using an investigational device.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 2 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXHas received any prior anti-cancer therapy, monoclonal antibody, chemotherapy, or an investigational agent or device before the first dose of study treatment, or has not recovered from AEs due to previously administered agentsXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatmentXx_NEWLINE_xXTreatment with any, investigational therapy within the 4 weeks prior to the initiation of study drug administrationXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXTreatment with any investigational agent within 14 days of first administration of study treatment is not permittedXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or used an investigational device within 4 weeks prior to the first dose of study treatment. Note: Subjects who have entered the follow-up phase of an investigational trial may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.Xx_NEWLINE_xXPatient is currently using, or planning to use another investigational agentXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.Xx_NEWLINE_xXAny other anti cancer agents (eg, hormonal, biological, investigational) within 5 times the half life prior to investigational product.Xx_NEWLINE_xXUse of any other investigational agents within 30 days of starting study treatmentXx_NEWLINE_xXPatients who have been treated with an investigational agent within 21 days prior to the first dose of study drug.Xx_NEWLINE_xXPlanned participation in another study of an investigational agent or investigational device or planned use of any other agent or therapeutic device intended for therapy of gliomaXx_NEWLINE_xXPatients who have participated in a study with an investigational agent or device within 2 weeks of enrollmentXx_NEWLINE_xXUse of an investigational agent within 4 weeks of enrollment (day 1)Xx_NEWLINE_xXUse of other investigational agent for prostate cancerXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatients who have participated in a study with an investigational agent or device within 2 weeks of initiation of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceiving any approved or investigational anti-cancer agent other than those provided for in this studyXx_NEWLINE_xXPatient is using or plans to use an investigational agent for the prevention of GvHD.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXInvestigational drug therapy outside of this trial during or within 4 weeks of first study treatmentXx_NEWLINE_xXIs currently participating and receiving trial therapy or has participated in a trial of an investigational agent and received trial therapy or used an investigational device within 4 weeks of the first dose of trial treatment.Xx_NEWLINE_xXTreatment with any investigational products within 14 days before the first dose of any study drugXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXCurrently receiving or have received any other investigational agent considered as a treatment for the primary neoplasm =< 21 days prior to registrationXx_NEWLINE_xXIs currently participating and receiving pembrolizumab or has participated in a study of an investigational agent and received pembrolizumab or used an investigational device within 4 weeks of the first dose of study treatment.Xx_NEWLINE_xXThe participant has received another investigational agent within 14 days of the first dose of study drugXx_NEWLINE_xXThe use of another investigational drug within the previous 30 daysXx_NEWLINE_xXNo investigational therapy within four weeks of the first dose of study drug.Xx_NEWLINE_xXReceived an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 14 days or 5 half lives before enrollment or is currently enrolled in the treatment stage of an investigational studyXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 28 days of the first dose of treatmentXx_NEWLINE_xXCurrent or planned participation in a study of an investigational agent or using an investigational deviceXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.Xx_NEWLINE_xXSubjects may not be receiving any other investigational agents or have participated in any other clinical trial involving another investigational agent for treatment of advanced solid tumors or lymphoma within 3 weeks prior to cycle 1, day 1 of the study.Xx_NEWLINE_xXIs currently participating in and receiving study therapy, or has participated in a study of an investigational agent and received study therapy, or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXParticipants who are receiving an investigational agent(s)Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXCurrently participating in a study of an investigational agentXx_NEWLINE_xXIs currently participating and receiving study therapy of an investigational agent and received study therapy within 2 weeks of the first dose of treatment; this 2 week washout period would not apply to investigational food ingredientsXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.Xx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasm =< 21 days prior to registrationXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasm or used an investigational device =< 4 weeks from registrationXx_NEWLINE_xXAnother investigational drug within 4 weeks of study drug administrationXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of on-study dateXx_NEWLINE_xXTreatment with any investigational agent within 14 days prior to being registered for protocol therapyXx_NEWLINE_xXCurrently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy, or herbal/complementary oral or IV medicine within 2 weeks of the first dose of treatmentXx_NEWLINE_xXNo treatment with any investigational agent for any medical condition within 28 days prior to being registered for protocol therapyXx_NEWLINE_xXSubjects who anticipate use of other investigational or non-investigational agents for the treatment of MDS during the study period, aside from a stable dose of erythropoietin stimulating agent started >8 weeks prior to screening for this study.Xx_NEWLINE_xXTreatment with any investigational agent within 28 days of first administration of study treatment.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 28 calendar days of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatients receiving another investigational agentXx_NEWLINE_xXSubjects participating in or who have participated in a study of an investigational agent or is using an investigational device within 4 weeks of the first dose of study treatment or have received any anti-cancer therapy, platinum-based chemotherapy, targeted, biological (including humanized antibodies), investigational, immunotherapy, or hormonal agent, within 4 weeks of the first dose of study treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXAdministration of any investigational agent within 4 weeks prior to initiating study treatmentXx_NEWLINE_xXTreatment with an investigational anti-cancer study drug within 4 weeks prior to study drug administration date.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceived any investigational agent within the 14 days before the start of study treatment (1st dose of fludarabine)Xx_NEWLINE_xXThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device =< 28 days of registrationXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatients who participated in any therapeutic clinical study with an investigational agent within the last 30 daysXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXAdministration of any investigational drug within 4 weeks prior to the first dose of study treatmentXx_NEWLINE_xXReceiving any other investigational agent(s) or has received an investigational agent within the last 30 daysXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first planned dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 2 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study treatment.Xx_NEWLINE_xXCytotoxic therapy or investigational agent use within 28 daysXx_NEWLINE_xXHave received other investigational drugs within 30 days of enrollment.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXTreatment with a non-approved or investigational drug within 30 days prior to day 1 of study treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXPatients who have received treatment with an investigational drug within 30 days preceding the first dose of study medicationXx_NEWLINE_xXReceiving any investigational agent, that would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXReceived another investigational agent (defined as any agent/device that has not received regulatory approval for any indication) within 14 days of the first dose of study drug for a nonmyelosuppressive agent, or 21 days of the first dose of study drug for a myelosuppressive agentXx_NEWLINE_xXCurrently enrolled in another investigational therapy protocol for AML.Xx_NEWLINE_xXPatients participating in another trial of an investigational agent within 4 weeks of the 1st dose of the studyXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXCurrently receiving treatment in another investigational device or drug study.Xx_NEWLINE_xXAnti-cancer therapy, including an investigational agent, less than 14 days prior to the first dose of nivolumabXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXCurrently receiving treatment with another investigational device or drug study, or < 28 days since ending treatment with another investigational device or drug study(s); other investigational procedures while participating in this study are excludedXx_NEWLINE_xXPatient is currently receiving or has received another investigational agent within 4 weeks prior to day 1 of studyXx_NEWLINE_xXTreatment with a prior investigational agent within 30 days of first dose of investigational medicationXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy with another investigational device or study drug or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatient is currently participating or has participated in a study of an investigational agent or using an investigational device within 28 days of the first dose of study drugXx_NEWLINE_xXReceived any investigational agent within the 14 days before the start of study treatment (1st dose of fludarabine)Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXCurrently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drugXx_NEWLINE_xXConcurrent enrollment on another investigational therapyXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of treatmentXx_NEWLINE_xXCurrently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device =< 4 weeks of the first dose of study drugXx_NEWLINE_xXAny previous treatment with a DDR agent, including any of the investigational agentsXx_NEWLINE_xXCurrently participating or has participated in a study of an investigational cancer therapy agent or using an investigational device within 28 days prior to study registrationXx_NEWLINE_xXBe at least 28 days from last administration of cytotoxic chemotherapy or other investigational agentXx_NEWLINE_xXHave received any investigational agent with known anti-CMV activity within 30 days before initiation of study treatment or CMV vaccine at any time.Xx_NEWLINE_xXHave received any unapproved agent or device within 30 days before initiation of study treatment.Xx_NEWLINE_xXNo investigational agents within 2 weeks prior to first study treatment.Xx_NEWLINE_xXConcurrent therapy with other investigational productsXx_NEWLINE_xXAn interval of >= 4 weeks after the last administration of any investigational agent or any other treatment prior to first dose of pembrolizumabXx_NEWLINE_xXPatients receiving any other investigational agent (s)Xx_NEWLINE_xXInvestigational drugs: subjects must not have received an investigational drug within 4 weeksXx_NEWLINE_xXCurrent or planned participation in a study of an investigational agent or using an investigational deviceXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatmentXx_NEWLINE_xXTreatment with any investigational products within 14 days before the first dose of any study drugXx_NEWLINE_xXReceiving any other investigational agentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatients who are currently receiving any other investigational agentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of day 1Xx_NEWLINE_xXExposure to any investigational drug within 4 weeks of study drug administrationXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating in a study of an investigational anti-cancer agent.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXCurrently receiving treatment in another investigational device or drug study, or less than 30 days between ending treatment on another investigational device or drug study(ies) and start of IP treatment. Other investigational procedures while participating in this study are excluded.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXAdministration of any investigational agent within 4 weeks prior to initiating study treatmentXx_NEWLINE_xXPrevious immunotherapy or investigational agents within 6 months of first administration of study drugXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPrevious immunotherapy or investigational agents within 6 months of first administration of study drugXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy, herbal/complementary oral or IV medicine, or used an investigation device within 4 weeks of the first dose of treatment; subjects must also have recovered from associated therapy (i.e., to grade =< 1 or baseline) and from adverse events due to any prior therapyXx_NEWLINE_xXParticipants who are receiving any other investigational agents or have received investigational therapy or any anti-cancer monoclonal antibody (mAB) within 4 weeks prior to the 1st dose of pembrolizumabXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy, herbal/complementary oral or IV medicine, or used an investigation device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceiving any other investigational agent, which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatients must not be receiving any other investigational agentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy, herbal/complementary oral or IV medicine, or used an investigation device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of the first dose of trial treatment; the 30 day window should be applied to the last dose of an antineoplastic investigational agent or last use of an investigational device with antineoplastic intentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceiving other investigational agentXx_NEWLINE_xXAt least 21 days have passed since receiving any investigational agent at the time of registrationXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the initiation of SBRTXx_NEWLINE_xXInvestigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXCurrently receiving an investigational agentXx_NEWLINE_xXTreatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatients who have received any other investigational agent =< 28 days prior to registration are not eligibleXx_NEWLINE_xXTreatment with a non-approved or investigational drug within 28 days of study treatmentXx_NEWLINE_xXReceipt of any investigational agent or study treatment within 30 days prior to C1D1Xx_NEWLINE_xXCurrent participation in or previous participation in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study treatmentXx_NEWLINE_xXmCRPC EXPANSION COHORT: The patient has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational new drug and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXNo treatment with any investigational agent within 30 days prior to being registered for protocol therapyXx_NEWLINE_xXOther investigational therapy (within 30 days of Study Day 1).Xx_NEWLINE_xXTreatment with another investigational agent currently or within 21 days prior to enrollment; patients may participate in other non-treatment studies concurrently if it will not interfere with participation in this studyXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXInvestigational therapy within 2 weeks of screeningXx_NEWLINE_xXIs currently participating and receiving a study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the study drug administrationXx_NEWLINE_xXConcurrent treatment with any other investigational agentXx_NEWLINE_xXTreatment with any investigational products within 14 days before the first dose of study drugXx_NEWLINE_xXTreatment with any investigational products within 3 weeks before the first dose of study drugXx_NEWLINE_xXConcurrent use of other investigational agents or Optune™ deviceXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently receiving active treatment with anti-cancer systemic chemotherapy, investigational agent, or biological therapyXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating in a study of an investigational agent and received an investigational agent within 4 weeks of the first dose of treatmentXx_NEWLINE_xXTreatment with other investigational agent(s) within 30 days of planned lymphodepletionXx_NEWLINE_xXTreatment with an investigational product during the last 2 weeksXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment or 5 half-lives, whichever is shorterXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of pembrolizumabXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatients may not be receiving any other investigational agents and may not have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXThe subject has participated or is currently participating in another study of an investigational medicine or medical device (radiotherapy, radio-immunotherapy, biological therapy, chemotherapy), within 4-weeks prior to screening.Xx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to the first dose of trial treatmentXx_NEWLINE_xXPHASE I AND PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Is currently participating in a study of an investigational agent or using an investigational device for therapeutic purposes; concurrent use of Optune device is not allowedXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment; an exception will be made for patients who have received CTL019 on experimental protocol; these patients will be eligible to enroll once progression of disease or failure to respond is documented by clinical or radiologic assessmentXx_NEWLINE_xXPatients must not have received an investigational anti-cancer drug within two weeks of start of protocol treatmentXx_NEWLINE_xXParticipation in any other investigational study or use of any other investigational agents within 30 days prior to study entryXx_NEWLINE_xXIs currently participating or has participated in a study of an investigational agent or using an investigational deviceXx_NEWLINE_xXCurrently receiving any other investigational agents, has participated in a study of an investigational agent, or use of an investigational device within 4 weeks of the first dose of pembrolizumabXx_NEWLINE_xXTreatment with any other investigational agent within 3 weeks prior to the first dose of MEDI4736 and tremelimumabXx_NEWLINE_xXIs currently participating in and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXCurrently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of MK-3475Xx_NEWLINE_xXConcurrent use of investigational therapeutic agentXx_NEWLINE_xXAny investigational agent within 4 weeks prior to initiating study treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.Xx_NEWLINE_xXReceiving or less than 21 days since receiving any other concurrent cytotoxic, biologic agent(s) or investigational agentXx_NEWLINE_xXSubjects must not have received any investigational agents within 30 days of study entryXx_NEWLINE_xXCurrently receiving or has had treatment with an investigational agent or used an investigational device within 4 weeks of study day 1Xx_NEWLINE_xXPHASE I: Patients who are receiving any other investigational agentXx_NEWLINE_xXPHASE II: Patients who are receiving any other investigational agentXx_NEWLINE_xXReceived investigational treatment in another clinical study within 4 weeks prior to the initiation of investigational treatment;Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study drug or using an investigation device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatients may not be receiving any other investigational agents; if patients are currently part of or have participated in any clinical investigation with an investigational drug, the last administration of the investigational study should be at least 1 month prior to dosingXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXInvestigational agent within 30 days of enrollment without approval from the sponsor- principal investigator (PI)Xx_NEWLINE_xXTreatment with any investigational products within 3 weeks before the first dose of study drugXx_NEWLINE_xXCurrently participating or has participated in a study of an investigational agent and received study therapy or received investigational device within 4 weeks prior to the first dose of study treatmentXx_NEWLINE_xXCurrently enrolled in another clinical study or used any investigational drug or device within 30 days (or 5 x half-life for investigational drugs where the half-life is known) preceding informed consentXx_NEWLINE_xXPatients currently participating or has participated in a study with an investigational compound or device within 4 weeks of initial dosing with study drugsXx_NEWLINE_xXReceived an investigational drug within 30 days of starting treatment, or have not recovered from side effects of an investigational drugXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXParticipation in another investigational drug study in the prior 4 weeksXx_NEWLINE_xXPatients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication within the past 2 weeks prior to initiation of CPI-613 treatment (the use of Hydrea is allowed)Xx_NEWLINE_xXAny investigational agent within 4 weeks prior to initiating study treatmentXx_NEWLINE_xXPatients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosingXx_NEWLINE_xXCurrently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s)Xx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent (except glutamine) or using an investigational device within 4 weeks of the first dose of treatment or 5 half lives, whichever is shorterXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXSubject is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study treatmentXx_NEWLINE_xXReceiving any other investigational agent(s) or has received an investigational agent within the last 30 daysXx_NEWLINE_xXConcurrent use of investigational therapeutic agentXx_NEWLINE_xXTreatment with any investigational compound within 30 days prior to the first dose of study drugsXx_NEWLINE_xXIs currently participating in a study of an investigational anti-cancer agentXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent (except glutamine) or using an investigational device within 2 weeks of the first dose of treatmentXx_NEWLINE_xXUse of any investigational product (IP) or investigational medical device within 28 days before day 1 of study drugXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatient may not be concurrently enrolled in another investigational drug treatment studyXx_NEWLINE_xXAny investigational agent within 4 weeks of study treatment initiationXx_NEWLINE_xXReceiving any other investigational agent(s) or has received an investigational agent within the last 30 daysXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXCurrently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXParticipation in any investigational drug study within 28 days prior to initiation of treatment within this protocol; (subject must have recovered from all acute effects of previously administered investigational agents)Xx_NEWLINE_xXSubject is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceipt of any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXCurrently receiving any other investigational agents, or received an investigational agent within 3 weeks of the first dose of nintedanibXx_NEWLINE_xXTREATMENT: Patients should have been off other investigational therapy for one month prior to entry in this studyXx_NEWLINE_xXUse of any investigational agent within 4 weeks prior to study entry.Xx_NEWLINE_xXPatients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past 2 weeks prior to initiation of treatment with study drugsXx_NEWLINE_xXTreatment with an investigational anti-cancer agent within 4 weeks prior to enrollment into the studyXx_NEWLINE_xXReceiving any other investigational agent(s) or has received an investigational agent within the last 30 daysXx_NEWLINE_xXExposure to any investigational agent within 30 days of date of randomization.Xx_NEWLINE_xXPatients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past 2 weeks prior to initiation of treatment with study drugsXx_NEWLINE_xXPatients receiving any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapyXx_NEWLINE_xXInvestigational compound within 4 weeks of enrollment or who are planning to receive other investigational agents while participating in this studyXx_NEWLINE_xXResearch participant must be at least 2 weeks out from having received the last dose of investigational agentXx_NEWLINE_xXInvestigational Drugs: Subjects who have received another investigational drug within the last 14 days are excluded from participation.Xx_NEWLINE_xXCurrently participating or has participated in a study of an investigational agent or using an investigational device within 28 days of administration of MK-4166Xx_NEWLINE_xXUse of any investigational agent within 4 weeks prior to the Baseline Visit.Xx_NEWLINE_xXPatient is currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study drugXx_NEWLINE_xXKnown or suspected drug sensitivity to cytarabine or the investigational agent ficlatuzumabXx_NEWLINE_xXPatients should not have received an investigational agent for at least 2 weeks prior to the first study drug doseXx_NEWLINE_xXPatients may not be receiving any other investigational agents and may not have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatients who are receiving investigational therapies or who have been treated with investigational therapies or investigational devices within 5 half-lives of the investigational therapy or 4 weeks of first scheduled day of dosing with PFK-158 if the half-live of the investigational agent is not known.Xx_NEWLINE_xXThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXThe use of any investigational agent in the month before enrollment into the studyXx_NEWLINE_xXRecent Investigational therapyXx_NEWLINE_xXParticipation in an investigational drug or device study or treatment with any antineoplastic agent within 14 days of the first day of dosing on this studyXx_NEWLINE_xXPatients currently receiving high dose systemic steroids for treatment of MM in excess of 320mg total dose of dexamethasone or equivalent, patients who received an investigational agent within 5 half-lives of the agentXx_NEWLINE_xXTreatment with other investigational drugs within 6 months of study entryXx_NEWLINE_xXPatient is currently participating or has participated in a study of an investigational agent or using an investigational device within 28 days of the first dose of study drugXx_NEWLINE_xXPatient has received other investigational drugs within 4 weeks before enrollmentXx_NEWLINE_xXParticipation in an investigational drug or device study within 14 days of the first day of dosing on this studyXx_NEWLINE_xXPatients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of the first scheduled day of protocol treatmentXx_NEWLINE_xXTreatment with a non-approved or investigational drug within 28 days of study treatmentXx_NEWLINE_xXPatient is simultaneously participating in another investigational drug or device studyXx_NEWLINE_xXAny other type of investigational agent within 4 weeks before the first dose of study treatmentXx_NEWLINE_xXInvestigational agent received within 30 days prior to the first dose of study drug; if received any investigational agent prior to this time point, drug-related toxicities must have recovered to grade 2 or less prior to first dose of study drugXx_NEWLINE_xXTreatment with any other investigational agent, or participation in another investigational drug trial within 28 days prior to randomizationXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXInvestigational agent within 4 weeks of first dose of study treatmentXx_NEWLINE_xXEnrollment in any other investigational treatment study or use of an investigational agent, or has not yet completed at least 3 half-lives since ending another investigational device or drug trialXx_NEWLINE_xXPatients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication within the past 2 weeks prior to initiation of CPI-613 treatmentXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXAny investigational drug within 4 weeksXx_NEWLINE_xXPatient is currently participating in a study with an investigational compound or deviceXx_NEWLINE_xXSubjects who participated in an investigational drug or device study within 28 days prior to study entryXx_NEWLINE_xXPatient has received other investigational drugs within 3 weeks before study registrationXx_NEWLINE_xXPatients may not have used any investigational agent within 4 weeks prior to enrollment into the studyXx_NEWLINE_xXPatients should have been off other investigational therapy for 4 weeks prior to entry in this studyXx_NEWLINE_xXWhile on this study, patients may not be treated with any other investigational agent for any purpose until relapse or progressionXx_NEWLINE_xXPatients who are receiving any other investigational agentXx_NEWLINE_xXPatients may not be receiving any other investigational agents and may not have participated in a study of an investigational agent or using an investigational device within five half-lives of the compound or 3 months, whichever is greaterXx_NEWLINE_xXTreated with any investigational therapy within 2 weeks of the first dose of study treatment.Xx_NEWLINE_xXReceived any investigational agent for any indication within 30 days prior to first treatment.Xx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXPrior treatment with any investigational drug within the preceding 4 weeksXx_NEWLINE_xXConcurrent enrollment in any other study using an investigational drugXx_NEWLINE_xXInvestigational agent: >= 28 days must have elapsed from treatment with a different investigational agentXx_NEWLINE_xXAdministration of any unlicensed or investigational agent within 4 weeks of entry to the studyXx_NEWLINE_xXNo prior investigational agent in the 4 weeks prior to initiation of therapyXx_NEWLINE_xXParticipation in an investigational drug study or history of receiving any investigational treatment within 30 days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatients who have received any investigational treatment agent within the last 28 days.Xx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the lymphomaXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 14 days of the first dose of treatment;Xx_NEWLINE_xXReceived an investigational drug, was vaccinated with live attenuated vaccines, or used an invasive investigational medical device within 4 weeks before the planned first dose of study drug, or is currently being treated in an investigational studyXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 2 weeks of the first dose of treatmentXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXPrior or current use of any investigational or commercially available anti-HCV agents other than interferon or ribavirin or receipt of any investigational product within 6 weeks prior to study drug administrationXx_NEWLINE_xXUse of investigational agent within 30 days of signing informed consentXx_NEWLINE_xXPatients who have received another investigational agent within the previous 3 monthsXx_NEWLINE_xXTreatment with any investigational products within 4 weeks before the first dose of any study drugXx_NEWLINE_xXUse of any investigational agent within 30 days of the first radiation doseXx_NEWLINE_xXUse of investigational agent within last 14 daysXx_NEWLINE_xXUse of any investigational agent within 4 weeks prior to study entry.Xx_NEWLINE_xXReceived any investigational agent within the 14 days before the start of ALT-803Xx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to the first dose of study drug.Xx_NEWLINE_xXIs currently participating and receiving study therapy with potential anti-neoplastic activity, or has participated in a study of an investigational agent and received study therapy with potential anti-neoplastic activity within 4 weeks of the first dose of treatmentXx_NEWLINE_xXUse of an investigational agent within 4 weeks of enrollmentXx_NEWLINE_xXTreatment with any other investigational agent within 28 days prior to enrolment.Xx_NEWLINE_xX4 weeks from any investigational agentXx_NEWLINE_xXReceived an investigational product or been treated with an investigational device within 30 days prior to first drug administration, or plans to start any other investigational product or device study within 30 days after last drug administration.Xx_NEWLINE_xXExposure to any investigational agent within 4 weeks prior to initiation of study treatment.Xx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXNo treatment with any investigational agent within 30 days prior to registration for protocol therapyXx_NEWLINE_xXLess than 4 weeks since use of another investigational agentXx_NEWLINE_xXTreatment with any investigational agent within 4 weeks prior to baselineXx_NEWLINE_xXTreatment with any investigational agent within 4 weeks prior baselineXx_NEWLINE_xXPatient on other investigational drugXx_NEWLINE_xXReceiving any other investigational agentXx_NEWLINE_xXNo investigational therapy within 4 weeks of first dose of study drugXx_NEWLINE_xXParticipation in another investigational study concurrently or use of another investigational drug within 6 months prior to administration of the first study vaccination;Xx_NEWLINE_xXSubjects who have received any investigational drugs or devices within 4 weeks before the first day of study treatment (C1D1).Xx_NEWLINE_xX201 Treatment within 30 days prior to enrollment with another investigational device or drug (interventional clinical study / studies). Other investigational procedures while participating in this study are excluded (observational studies are permitted).Xx_NEWLINE_xXPatients who have received treatment with any other investigational agent within 4 weeks before initiation of study treatmentXx_NEWLINE_xXAny antineoplastic agent for the primary malignancy (standard or investigational) without delayed toxicity within 4 weeks prior to first administration of IMP and during study with exceptionsXx_NEWLINE_xXAny other investigational agent or used an investigational device within 21 days prior to day 1 of protocol therapyXx_NEWLINE_xXTreatment with any other investigational anti-leukemia agentXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.Xx_NEWLINE_xXCurrently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXNon-nitrosourea cytotoxic drug or any systemic investigational agent with exception of methotrexate ? 4 weeksXx_NEWLINE_xXAny investigational agent(s) within 4 weeks prior to entryXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): Patient may not be currently participating and receiving study therapy or have participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXCurrently receiving any other investigational agents, or exposure to any investigational drug or placebo within 4 weeks of study treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent within 4 weeks of the first dose of treatmentXx_NEWLINE_xXRENAL COHORT: The subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXTreatment with any other investigational agent or investigational device within 4 weeks prior to registration (or within five half-lives of the investigational product, whichever is longer); patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (also referred to as an “early phase I study” or “pre phase I study” where a sub- therapeutic dose of drug is administered) at the coordinating center principal investigator (PI)’s discretion, and should have recovered to eligibility levels from any toxicitiesXx_NEWLINE_xXTreatment with other investigational agent within 4 weeks to the first dose of tremelimumab or durvalumabXx_NEWLINE_xXInvestigational therapy within 3 weeks.Xx_NEWLINE_xXPatient is currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of the firs dose of study drug (a patient in the survival follow up phase of an investigational agent where no further treatment is expected is eligible)Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy, or has participated in a study of an investigational agent and received study therapy, or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatmentXx_NEWLINE_xXPatient has participated in a prior investigational study within 3 weeks prior to initiating study drug.Xx_NEWLINE_xXPatient may not be concurrently enrolled in another investigational drug treatment studyXx_NEWLINE_xXParticipation in any investigational drug study within 4 weeks preceding the start of study treatmentXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXTreatment with any investigational agent within 28 days prior to registration for protocol therapyXx_NEWLINE_xXTreatment with any other investigational agent, or participation in another investigational drug trial within 28 days prior to randomizationXx_NEWLINE_xXPatient who has participated in a prior investigational study within 30 days prior to enrollmentXx_NEWLINE_xXNo investigational agents within 4 weeks from initiation of study treatmentXx_NEWLINE_xXUse of other investigational drugsXx_NEWLINE_xXCurrently participating and receiving study therapy, or have participated in a study of an investigational agent and received study therapy, or used an investigational device =< 4 weeks of registrationXx_NEWLINE_xXHave received any investigational agent with known anti-CMV activity within 30 days before initiation of study treatment or investigational CMV vaccine at any time.Xx_NEWLINE_xXHave received any unapproved agent or device within 30 days before initiation of study treatment.Xx_NEWLINE_xXTreated with any investigational drug within 2 weeks of the first dose of study treatment.Xx_NEWLINE_xXEnrollment concurrently in another investigational drug study or within 4 weeks of registrationXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXHas received study therapy (including investigational device) as part of a clinical trial within 4 weeks of the first dose of treatment, with the exclusion of an anti-PD1/L1 antibody given as either a single agent or non-CTLA-4 antibody containing combinationXx_NEWLINE_xXTreatment with investigational therapy within 14 days prior to initiation of study drugXx_NEWLINE_xXThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXAny investigational agent within 4 weeks prior to initiating study treatmentXx_NEWLINE_xXInvestigational therapy within 28 days prior to initiation of study treatmentXx_NEWLINE_xXTreatment with any investigational agent within 30 days prior to registration for protocol therapyXx_NEWLINE_xXOngoing treatment with any other cancer therapy or investigational agent, with the exception of intrathecal (IT) chemotherapy for leukemia, when indicatedXx_NEWLINE_xXTREATMENT: Patients who have had prior treatment with any of the other investigational agents or combinations on this protocol are eligible but will not receive the same investigational agent (everolimus or trametinib) or combination (AZD1775/combination or veliparib/temozolomide); instead, patients will receive an investigational agent or combination prospectively identified to work on a different target in their tumor’s mutation/aberrant pathwayXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXConcurrent treatment with an investigational agentXx_NEWLINE_xXDOSE ESCALATION COHORT: Current or anticipated use of other investigational agents while participating in this studyXx_NEWLINE_xXDOSE EXPANSION COHORT: Current or anticipated use of other investigational agents while participating in this studyXx_NEWLINE_xXPatients who have participated in a study with an investigational agent or device within 2 weeks of initiation of treatmentXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasm OR participated in a study of an investigational agent, received study therapy or used an investigational device =< 4 weeks prior to registrationXx_NEWLINE_xXSubjects must not have received any investigational agents within 30 days of study entryXx_NEWLINE_xXTreatment with any investigational drug within 30 days prior to registration.Xx_NEWLINE_xXParticipants who are receiving, or have received, any other investigational drugs or devices within the 2 weeks prior to the first dose of study medicationsXx_NEWLINE_xXAn interval of >= 4 weeks after the last administration of any investigational agent, bevacizumab, or prior cytotoxic therapyXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation) or receiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXTreatment with any investigational agent within 14 days prior to being registered for protocol therapyXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 2 weeks of the first protocol treatmentXx_NEWLINE_xXPatients who are currently participating in or have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXInvestigational therapy within 4 weeks of Screening.Xx_NEWLINE_xXTreatment with other investigational products within the last 2 months prior to entry into this studyXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation) or receiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment; Note: participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agentXx_NEWLINE_xXPatient is receiving any other investigational agentXx_NEWLINE_xXSubjects having received any other investigational agents within 4 weeks prior to the\n             first study drug administration and have not recovered completely (to AEs <  Grade 2)\n             from the side effects of the earlier investigational agentXx_NEWLINE_xXPrior investigational immunotherapyXx_NEWLINE_xXConcurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 28 days prior to registrationXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXUse of an investigational agent within the previous 28 days of study registrationXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatient is concurrently using other approved or investigational antineoplastic agentXx_NEWLINE_xXTreatment with any investigational agent within two weeks prior to first dose in this study; hydroxyurea is allowed to control the AML prior to treatment on the studyXx_NEWLINE_xXIs currently participating in or has participated in any study of an investigational agent or using an investigational device within 4 weeks of transplant admissionXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXPatients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication within the past 2 weeks prior to initiation of CPI-613 treatment (the use of Hydrea is allowed)Xx_NEWLINE_xXPatients must not be receiving any other investigational agentXx_NEWLINE_xXPatients may not be receiving any other investigational agents at time of study entry or at any time while on study or be on another investigational agent that can impact on the primary clinical outcome analyses or has known pharmacodynamics or pharmacokinetic effects on AATXx_NEWLINE_xXPatients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of IPHC (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)Xx_NEWLINE_xXPatients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of HIPEC (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)Xx_NEWLINE_xXReceiving any other investigational agentXx_NEWLINE_xXConcurrent treatment with an investigational agent other than the investigational agent(s) used in this study OR treatment within 4 weeks of study entry with any investigational agent(s) or device(s)Xx_NEWLINE_xXPatients who have received any investigational agent within 30 days prior to day 1Xx_NEWLINE_xXPatient is currently participating or has participated in a study with an investigational compound or devise within 30 days of initial dosing with study drug(s)Xx_NEWLINE_xXAny investigational drug < 6 weeks prior to the first dose of study drug or not recovered from effects of prior investigational agentXx_NEWLINE_xXCurrently participating and receiving treatment in another study, or participated in a study of an investigational agent and received treatment, or used an investigational device within 4 weeks of randomizationXx_NEWLINE_xXUse of any other investigational drugXx_NEWLINE_xXIs currently participating, or has participated in a study of an investigational agent and received study drug, herbal/complementary oral or IV medicine, or used an investigational device within 4 weeks of the first dose of study drug. Participants must also have recovered from associated therapy (i.e., to Grade ?1 or baseline) and from adverse events (AEs) due to any prior therapy.Xx_NEWLINE_xXAny intravesicular or other chemotherapy treatment within 2 weeks or any investigational agent within 4 weeks prior to the initial dose of study drug.Xx_NEWLINE_xXSubjects who received any investigational agent ?28 days of study drug initiation.Xx_NEWLINE_xXSubjects who received an investigational agent <14 days prior to their first day of study drug administration.Xx_NEWLINE_xXIs currently participating in and receiving study therapy or has participated in a study of an investigational agent and received study drug or used an investigational device within 4 weeks of treatment allocationXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.Xx_NEWLINE_xXCurrently participating in and receiving study therapy or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study medicationXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks of the first dose of study drug.Xx_NEWLINE_xXPatient has participated in an investigational research study using an investigational agent within the last 30 days prior to screeningXx_NEWLINE_xXPatients who have participated in a prior investigational study within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXSubject participating in any other study involving an investigational (unapproved) drug or device within the past 60 days.Xx_NEWLINE_xXConcurrent therapy with any other investigational drugXx_NEWLINE_xXThe patient has received treatment with another investigational agent within 14 days of study entry.Xx_NEWLINE_xXAny other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXConcomitant use of any other investigational drugsXx_NEWLINE_xXPatients who were currently receiving any other investigational agent.Xx_NEWLINE_xXAny investigational agents from a previous clinical study within 4 half-lives of said prior investigational agent(s) with regard to the first dose of study treatment on this protocol.Xx_NEWLINE_xXConcurrent treatment with other investigational drugs.Xx_NEWLINE_xXIs currently participating in and receiving study therapy or has participated in a study of an investigational agent or used an investigational device within 4 weeks of the first dose of study therapyXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to allocation, has had major surgery within 4 weeks or radiation therapy within 2 weeks prior to allocation, or who has not recovered (i.e., ? Grade 1 or to Baseline) from AEs due to prior treatment.Xx_NEWLINE_xX? 28 days elapsed from the administration of any investigational agentXx_NEWLINE_xXAny anti-cancer treatment within 14 days or any investigational agent within 30 days before the first dose of study drug.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to administration of pembrolizumab.Xx_NEWLINE_xXUse of any investigational agent within the 4 weeks preceding enrollmentXx_NEWLINE_xXAny investigational agent within 3 weeks of Day 1 of trial drug treatmentXx_NEWLINE_xXParticipated in any other study in which receipt of an investigational new drug or investigational device occurred within 28 days of first dose of study drugXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to randomization.Xx_NEWLINE_xXCurrently participating or has participated in a study (treatment period only) of an investigational agent or used an investigational device within 28 days of enrollmentXx_NEWLINE_xXFirst day of dosing with tesevatinib is less than 2 weeks from treatment with another investigational agentXx_NEWLINE_xXCurrently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to the first dose of study drugXx_NEWLINE_xXCurrently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug studyXx_NEWLINE_xXReceived an investigational agent within 4 weeks prior to enrollmentXx_NEWLINE_xXSubject is currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of the first dose of study treatmentXx_NEWLINE_xXCurrently receiving treatment in another investigational device or drug study or less than 30 days since ending treatment on another investigational device or drug study. Other investigational procedures while participating in this study are excluded.Xx_NEWLINE_xXInvestigational drug within 30 days of first trilaciclib (G1T28) doseXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.Xx_NEWLINE_xXPreviously received an investigational antineoplastic agent for NSCLC.Xx_NEWLINE_xXUse of any investigational agent within 28 days of randomization.Xx_NEWLINE_xXPatients who have received treatment with any other investigational agent within 4 weeks before enrollment.Xx_NEWLINE_xXNo investigational agent within 4 weeks prior to first dose of study drug.Xx_NEWLINE_xXEnrollment on any additional investigational agent study. Enrollment on concurrent observational study is allowed following consultation with the Sponsor.Xx_NEWLINE_xXHave been treated with an investigational agent within 4 weeks prior to the first day of IP administration.Xx_NEWLINE_xXCurrently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of administration of pembrolizumabXx_NEWLINE_xXInvestigational therapy within 4 weeks of Screening.Xx_NEWLINE_xXAnti-cancer therapy or any treatment with an investigational agent within 30 days prior to randomizationXx_NEWLINE_xXCurrently receiving or has received an investigational treatment as part of a study of an investigational agent or has used an investigational device within 4 weeks before randomization.Xx_NEWLINE_xXTreatment with investigational therapy within 28 days prior to initiation of study treatmentXx_NEWLINE_xXCurrent or recent treatment with another investigational drug within 30 days of first study treatment dosing or earlier participation in this studyXx_NEWLINE_xXAdministration of any investigational agent within 28 days of first dose of study drugXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy, herbal/complementary oral or IV medicine, or used an investigational device within 4 weeks of the first dose of study drug. Participant must also have recovered from associated therapy (i.e., to Grade ?1 or baseline) and from adverse events due to any prior therapyXx_NEWLINE_xXIs currently participating in or has participated in a clinical study and received an investigational agent or used an investigational device within 4 weeks prior to the first dose of study treatmentXx_NEWLINE_xXAny investigational agent within the previous 30 days.Xx_NEWLINE_xXOther investigational therapiesXx_NEWLINE_xXTreatment with any other investigational agent within 28 days prior to registration. Subjects must not be treated with any other investigational agent while on protocol specified therapy.Xx_NEWLINE_xXCurrent or recent (within 30 days of first study dosing) treatment with another investigational drug or participation in another investigational studyXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXTreatment with radiotherapy, any chemotherapeutic agent, systemic steroids used as an anti-neoplastic agent, or any other investigational anti-cancer agent within 2 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXAnother investigational drug within 4 weeks of study drug administrationXx_NEWLINE_xXConcurrent use of another investigational drug or device therapy (ie, outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form).Xx_NEWLINE_xXConcurrent participation in any other investigational studyXx_NEWLINE_xXPrior or concurrent exposure to any of the following: approved or investigational treatments for SMM or/and multiple myeloma, daratumumab or other anti CD-38 therapies, treatment with corticosteroids with a dose greater than (>) 10 milligram (mg) prednisone per day or equivalent and bone-protecting agents (eg, bisphosphonates, denosumab) or are only allowed if given in a stable dose and for a nonmalignant condition, or received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 4 weeks before Cycle 1, Day 1Xx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatient is concurrently using other approved or investigational antineoplastic agentXx_NEWLINE_xXParticipation in any other investigational drug trial or exposure to other investigational agent, device or procedure within 30 daysXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatients who are currently part of or have participated in any clinical investigation with an investigational drug within 30 days prior to dosing.Xx_NEWLINE_xXParticipation in any investigational drug study within 4 weeks preceding the start of study treatment; patients are not permitted to participate in another investigational drug study while being treated on this protocolXx_NEWLINE_xXParticipation in a therapeutic investigational study within 4 weeks prior to enrollment, or anticipated treatment with another investigational product while on study; this refers to non-commercially approved investigational drugs different than those used in this protocolXx_NEWLINE_xXCurrently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of first dose of study drugXx_NEWLINE_xXCurrently receiving or has received any investigational drugs within the 14 days prior to the first dose of study drug (day -7)Xx_NEWLINE_xXTreatment with any other investigational agentXx_NEWLINE_xXExposure to any investigational drug within 4 weeks of study drug administrationXx_NEWLINE_xXInvestigational agent received within 30 days prior to the first dose of study drugXx_NEWLINE_xXCurrently participating or has participated in a study using an investigational antineoplastic agent or device within 30 days of first doseXx_NEWLINE_xXOther investigational agents within 21 days prior to study treatment.Xx_NEWLINE_xXThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXAnother investigational drugXx_NEWLINE_xXNo treatment with any investigational agent within 30 days prior to registration for protocol therapy.Xx_NEWLINE_xXExposure to any investigational agent, systemic chemotherapy, or therapeutic radiation within 21 days of enrollment (Part 1) or randomization (Part 2).Xx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXInvestigational agent within 21 days prior to day 1 of protocol therapyXx_NEWLINE_xXPreviously received treatment with RGX-104 or another investigational agent that is a known LXR agonist.Xx_NEWLINE_xXParticipation in an interventional, investigational study within 2 weeks of the first dose of study treatment.Xx_NEWLINE_xXPatients currently participating and receiving study therapy or who have participated in a study of an investigational agent and received study therapy or used and investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXParticipant has received an investigational drug or used an invasive investigational medical device within 30 days prior to Study Entry or is currently enrolled in an investigational studyXx_NEWLINE_xXPatients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosingXx_NEWLINE_xXTreatment with a non-approved or investigational drug within 30 days before day 1 of study treatmentXx_NEWLINE_xXPatients on other investigational drugs while on study will be excludedXx_NEWLINE_xXTreatment with an investigational agent within 4 weeks of starting treatment.Xx_NEWLINE_xXUse of an investigational agent or an investigational device within 28 days before administration of first dose of NKTR-214.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXSubject is currently participating or has participated in another clinical trial within the past 30 days and is receiving/has received an investigational drug, device, or biologic agent; andXx_NEWLINE_xXConcurrent use of another investigational drug or device (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)Xx_NEWLINE_xXUsed an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatient is concurrently using other approved or investigational antineoplastic agentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXCurrently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study medicationXx_NEWLINE_xXParticipant is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to administration of pembrolizumab and CC-486Xx_NEWLINE_xXAdministration of any investigational agent within 28 days of first dose of study drugXx_NEWLINE_xXPatient is currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of administration of study therapyXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXTreatment with any investigational agent within three weeks prior to first dose in this studyXx_NEWLINE_xXConcurrent use of investigational therapeutic agentXx_NEWLINE_xXCurrently participating in another study and receiving trial treatment, participated in a study of an investigational agent and received trial treatment within 4 weeks of the first dose of medication in this study, or used an investigational device within 4 weeks of the first dose of medication in this study.Xx_NEWLINE_xXReceived an investigational agent within 30 days prior to registrationXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study drug or using an investigation device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or is or has been using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXTreatment with any investigational agent within 28 days of first administration of study treatmentXx_NEWLINE_xXOther concurrent experimental or investigational drugsXx_NEWLINE_xXTreatment with any investigational agent within three weeks prior to first dose in this studyXx_NEWLINE_xXCurrently receiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 2 weeks (4 weeks for monoclonal antibodies) of the first dose of treatmentXx_NEWLINE_xXUse of an investigational agent within 4 weeks before the screening visit;Xx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of registration. Subjects are not permitted to participate in another investigational drug study while being treated on this protocol.Xx_NEWLINE_xXCurrently participating and receiving study therapy, or participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks of the first dose of medicationXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXCurrently participating and receiving study therapy, or participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks of the first dose of study medicationXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXCurrently participating and receiving study therapy, or participated in a study of an investigational agent and received study therapy, or used an investigational device within 4 weeks of the first dose of study medicationXx_NEWLINE_xXTaking an investigational agent within 4 weeks of initiation of everolimusXx_NEWLINE_xXReceived other cancer treatment or investigational drug within 4 weeks prior to screeningXx_NEWLINE_xXParticipants should not have received any other investigational agents nor have participated in an investigational trial within the past 4 weeksXx_NEWLINE_xXTreatment with any investigational agent within 28 days prior to registration for protocol therapyXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device 4 weeks since last dose of agent administrationXx_NEWLINE_xXCurrent or planned participation in a study of an investigational agent or using an investigational deviceXx_NEWLINE_xXCurrently participating or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study treatmentXx_NEWLINE_xXSubjects who have received investigational agents within 28 days of the first day of study drug.Xx_NEWLINE_xXUse of investigational agents of any kind within 30 days before study treatmentXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 2 weeks of the radiation therapyXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXReceiving any other investigational agent =< 4 weeks prior to registration which would be considered as treatment for the primary neoplasmXx_NEWLINE_xXPatient who has participated in a prior therapeutic investigational drug study within 30 days prior to enrollmentXx_NEWLINE_xXParticipation in another investigational drug study in the prior 8 weeksXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatient is currently participating in or has participated in a study of an investigational systemic agent to treat MCC; or is using an investigational device within 4 weeks of the first dose of treatment\r\n* NOTE: if patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Toxicity from surgery or associated interventions that has not recovered to =< grade 1 is allowed if it meets the inclusion requirements for laboratory parametersXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXCurrently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to the first dose of trial medicationXx_NEWLINE_xXCurrently receiving treatment in a study of an investigational agent or using an investigational device <= 4 weeks prior to the first dose of trial medicationXx_NEWLINE_xXCurrently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to randomizationXx_NEWLINE_xXPatient has received an investigational agent or used an investigational device within 28 days of the first dose of study drugXx_NEWLINE_xXPatients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosingXx_NEWLINE_xXPatients must not have prior treatment with any investigational drug within the preceding 28 days and must not be planning to receive any other investigational drug for the duration of the studyXx_NEWLINE_xXPatients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosingXx_NEWLINE_xXParticipation in any investigational drug study within 28 days prior to initiation of treatment within this protocol; (subject must have recovered from all acute effects of previously administered investigational agents)Xx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXParticipation in any other research protocol involving administration of an investigational agent within 6 weeks prior to study entryXx_NEWLINE_xXTreatment with any investigational products within 60 days before the first dose of the study drug regimen.Xx_NEWLINE_xXParticipants who received any investigational treatment within 4 weeks of study startXx_NEWLINE_xXOther investigational treatment during or within 21 days before starting study treatmentXx_NEWLINE_xXConcurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 21 days of trial entry (signing of the informed consent form)Xx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXAt least 4 weeks must have elapsed from the use of any other investigational agent prior to starting study drugXx_NEWLINE_xXPatients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosingXx_NEWLINE_xXTreatment with investigational therapy within 2 weeks of study treatmentXx_NEWLINE_xXUse of investigational agent within 28 days prior to RandomizationXx_NEWLINE_xXPatients receiving other investigational agentXx_NEWLINE_xXConcurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)Xx_NEWLINE_xXInvestigational drugs: subjects must not have received an investigational drug within 4 weeksXx_NEWLINE_xXAny investigational agent, chemotherapy, immunotherapy, biologic, hormonal within 28 days of the first dose of study treatmentXx_NEWLINE_xXSubjects who received an investigational agent <14 days prior to their first day of study drug administration. In addition, the first dose of AG-120 should not occur before a period ?5 half-lives of the investigational agent has elapsed.Xx_NEWLINE_xXUse of an investigational agent within 2 weeks of enrollment (day 1 visit)Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXCurrently receiving another investigational agentXx_NEWLINE_xXUse of any investigational product or investigational medical device within 28 days prior to enrollmentXx_NEWLINE_xXParticipation in any investigational drug study within 4 weeks preceding the start of study treatmentXx_NEWLINE_xXPatient who will be receiving another investigational product during the studyXx_NEWLINE_xXReceived an investigational agent within 4 weeks prior to enrollmentXx_NEWLINE_xXSubjects who are receiving any other investigational agents or who have received an investigational agent within 28 days prior to enrollment (does not apply to participation in survival follow up), or who have previous exposure to vandetanibXx_NEWLINE_xXReceiving any other concurrent cytotoxic, biologic agent(s) or investigational agentXx_NEWLINE_xXReceiving another investigational agent (30 day wash-out required prior to first dose)Xx_NEWLINE_xXCurrently receiving treatment in a different clinical study in which investigational procedures are performed or investigational therapies are administeredXx_NEWLINE_xXHistory of receiving any investigational treatment within 21 days prior to enrollment into the studyXx_NEWLINE_xXIf a subject previously received investigational treatment, the last dose of investigational treatment was administered within 4 weeks of Day 1 of the study or adverse event(s) attributable to investigational treatment have not resolved to Grade 1 or better.Xx_NEWLINE_xXAny investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment;Xx_NEWLINE_xXSubjects must have received their last dose of investigational or biologic agent >= 7 days prior to study registration\r\n* In the event that a subject has received an investigational or biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to registration\r\n* If the investigational or biologic agent has a prolonged half-life (>= 7 days) then at least three (3) weeks must have elapsed prior to registrationXx_NEWLINE_xXThe patient has received any investigational therapy ? 28 days prior to start of Investigational Product. Investigational therapy is defined as any medicinal product that is not approved in the country of treatment for any indication, adult or pediatric.Xx_NEWLINE_xXUse of any investigational agent within 4 weeks prior to study entry.Xx_NEWLINE_xXReceipt of treatment with another investigational device or drugXx_NEWLINE_xXNo treatment with any investigational agent within 30 days prior to study registration.Xx_NEWLINE_xXParticipation in any other investigational drug study within 4 weeks of study enrollmentXx_NEWLINE_xXPatient is currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study drugXx_NEWLINE_xXCurrent or anticipated use of other investigational agents while participating in this studyXx_NEWLINE_xXReceived ibrutinib or following therapies considered investigational for treatment of cGVHD including imatinib, bortezomib, ruxolitnib, or entospletinib, within 4 wks prior to starting AMG 592 or is currently receiving treatment in another investigational drug or device study.Xx_NEWLINE_xXCurrently participating and receiving another study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy in a study of an investigational agent or has participated and received study therapy in a study of an investigational agent or has used an investigational device within 28 days of administration of MK-3475Xx_NEWLINE_xXTreatment with any investigational products within 4 weeks before the first dose of any study drugXx_NEWLINE_xXCurrent enrollment in an investigational drug or device study or participation in such a study within 30 days of enrollmentXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXPatients receiving any other standard or investigational treatment for their cancer, or any investigational agent for any non-cancer indication within the past 2 weeks prior to initiation of CPI-613 treatmentXx_NEWLINE_xXSubjects who received a small molecule investigational agent <14 days prior to their first day of study drug administration. In addition, the first dose of AG-221 should not occur before a period ?5 half-lives of the investigational agent has elapsed.Xx_NEWLINE_xXTreatment with any investigational products within 30 days before the first dose of study drugXx_NEWLINE_xXConcomitant use of any other investigational drugsXx_NEWLINE_xXReceipt of an investigational agent within 30 days (or 60 days for an antibody-based therapy) before the first planned dose of study drugsXx_NEWLINE_xXPatients who have participated in a window study (treatment with an investigational agent prior to surgery for =< 2 weeks) are eligible; patients must have discontinued the investigational agent at least 14 days before participationXx_NEWLINE_xXTreatment with any investigational products within 60 days before the first dose of the study drug regimenXx_NEWLINE_xXConcurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)Xx_NEWLINE_xXPatients who have received any investigational agent within 4 weeks of enrollmentXx_NEWLINE_xXPatients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication within the past 2 weeks prior to initiation of CPI-613 (6,8-bis[benzylthio]octanoic acid) treatmentXx_NEWLINE_xXReceipt of any other investigational agent within the 28 days prior to Day 1.Xx_NEWLINE_xXTreatment with an investigational agent ? 30 days prior to randomizationXx_NEWLINE_xXPatients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication within the past 2 weeks prior to initiation of CPI-613 treatmentXx_NEWLINE_xXParticipation in an investigational therapeutic study within 3 weeks prior to first doseXx_NEWLINE_xXHaving received an investigational agent within 30 days prior to the first dose of study treatmentXx_NEWLINE_xXParticipation in any investigational drug study within 4 weeks preceding the start of study treatmentXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXPrior treatment with any investigational drug within the preceding 4 weeksXx_NEWLINE_xXConcurrent therapy with any other investigational agentXx_NEWLINE_xXConcurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)Xx_NEWLINE_xXPrevious exposure to any investigational treatment within 30 days before the first dose of study treatmentXx_NEWLINE_xXReceiving any other investigational agent that would be considered a treatment for the primary neoplasmXx_NEWLINE_xXPatients that are receiving any other investigational agentXx_NEWLINE_xXTreatment with any investigational drug within 2 weeks before first administration of present trial drug.Xx_NEWLINE_xXTreatment with a non-approved or investigational drug within 30 days before visit 1Xx_NEWLINE_xXTaking other investigational drugsXx_NEWLINE_xXTreatment with a systemic investigational agent within 28 days before the screening visit.Xx_NEWLINE_xXThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXPatient has received an investigational agent or cytotoxic chemotherapy (excluding hydroxyurea) within 2 weeks of studyXx_NEWLINE_xXTreatment with an investigational agent within 4 weeks before dosingXx_NEWLINE_xXTreatment with any investigational agent within 14 days of first administration of study treatmentXx_NEWLINE_xXPatients who have not yet completed at least 21 days (30 days for prior monoclonal antibody therapy) since ending other investigational device or drug trials, or who are currently receiving other investigational treatmentsXx_NEWLINE_xXPatients who have received any other investigational agent in a 28-day period prior to enrollment in this studyXx_NEWLINE_xXReceiving any investigational agent currently, or within 2 weeks of day 1 of treatment on this studyXx_NEWLINE_xXOngoing treatment with any other investigational therapyXx_NEWLINE_xXParticipation in any investigational drug study within 4 weeks preceding the start of study treatmentXx_NEWLINE_xXConcomitant use of any other investigational drugsXx_NEWLINE_xXThe participant has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXPrior treatment with any investigational drug within the preceding 4 weeksXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXConcurrent use of other investigational agents and patients who have received investigational drugs =< 4 weeks prior to enrollmentXx_NEWLINE_xXIndividuals who have received any investigational drug within 4 weeksXx_NEWLINE_xXConcurrent use of any other investigational productXx_NEWLINE_xXParticipation in any investigational drug study within 4 weeks preceding the start of study treatmentXx_NEWLINE_xXPatient has received other investigational drugs within 3 weeks before study registrationXx_NEWLINE_xXCurrently participating or enrolled in another investigational treatment, device or drug study through follow upXx_NEWLINE_xXUse of an investigational agent, including an investigational anti-cancer agent, within 14 days prior to the first dose of study drugXx_NEWLINE_xXTreatment with investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXPatients receiving other investigational medication (including investigational immunotherapy for NSCLC) or having received such medication within 30 days before entering the protocolXx_NEWLINE_xXPatients receiving any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapyXx_NEWLINE_xXCurrent enrollment in any other investigational treatment studyXx_NEWLINE_xXTreatment with any investigational agent within 14 days prior to being registered for protocol therapyXx_NEWLINE_xXPatients who are using other investigational agents or who had received investigational drugs =< 4 weeks prior to study treatment startXx_NEWLINE_xXNo use of an investigational agent within 2 weeks of starting ECPXx_NEWLINE_xXPatient is currently participating or has participated in a study with an investigational compound or device within 30 days of Study Day 1Xx_NEWLINE_xXPatients receiving an investigational agent within 30 days before enrollmentXx_NEWLINE_xXSubjects participating in or who have participated in a study of an investigational agent or is using an investigational device within 4 weeks of the first dose of study treatment or have received any anti-cancer therapy, chemotherapy, targeted, biological (including humanized antibodies), investigational, immunotherapy, or hormonal agent, within 4 weeks of the first dose of study treatmentXx_NEWLINE_xXConcurrent enrollment in another therapeutic investigational clinical study or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drugXx_NEWLINE_xXCurrently receiving a study therapy or if they had an investigational agent within 4 weeks at the time of enrollment.Xx_NEWLINE_xXIs currently participating and receiving study treatment or has participated in a study of an investigational agent and received study treatment or used an investigational device within 4 weeks of the first dose of treatment for another health-related problemXx_NEWLINE_xXCurrent active treatment with an investigational agentXx_NEWLINE_xXIs currently participating in or has participated in an interventional clinical study with an investigational compound or device within 4 weeks of the first dose of treatment in this current study.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXAny investigational agent within 4 weeks of first dose of study treatmentXx_NEWLINE_xXPatient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drug(s)Xx_NEWLINE_xXPatient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drug(s)Xx_NEWLINE_xXTreatment with systemic investigational drug within 4 weeks or topical investigational drug within 7 days of study startXx_NEWLINE_xXTreatment with a an investigational agent within 30 days prior to the first dose of dasatinib/ATRA or planning to receive an investigational agent during the studyXx_NEWLINE_xXNo other concurrent investigational treatmentXx_NEWLINE_xXAn investigational agent within the past 30 daysXx_NEWLINE_xXCurrent use of an investigational agentXx_NEWLINE_xXAny investigational agent, other than NEOD001, within 4 weeksXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXTreatment with any investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXSubjects who participated in any other investigational drug trial or had exposure to any other investigational agent, device or procedure <4 weeks prior to Screening and throughout the entire trial, with the exception of investigational drugs administered prophylactically for CMV post allogeneic HCT.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXHas participated in a study of an investigational agent and received study therapy or used an investigational device within 28 days of study startXx_NEWLINE_xXTreatment with any investigational agent within 28 days prior to registration.Xx_NEWLINE_xXPatients must not be receiving any other investigational agentXx_NEWLINE_xXParticipation in an investigational research study using an investigational agent within 30 days of screeningXx_NEWLINE_xXBe currently enrolled in another investigational treatment protocolXx_NEWLINE_xXSubject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or investigational drug study(s), or subject is receiving other investigational agent(s)Xx_NEWLINE_xXParticipant has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this studyXx_NEWLINE_xXReceiving any other concurrent cytotoxic, biologic agent(s) or investigational agent; NOTE: Concurrent intrathecal chemotherapy for CNS prophylaxis allowed per institutional standardsXx_NEWLINE_xXOngoing investigational treatmentXx_NEWLINE_xXUse of an investigational therapeutic agent with 4 weeks of enrollmentXx_NEWLINE_xXTreatment with an investigational agent within 30 days prior to the first dose of SNX?5422 or planning to receive an investigational agent during the study.Xx_NEWLINE_xXExposure to an investigational product or investigational device in another clinical study within 4 weeks prior to C1D1, or is scheduled to participate in another clinical study involving an investigational product or device during the course of this studyXx_NEWLINE_xXHaving received an investigational agent with 21 days of receiving the first dose of study drug on this trialXx_NEWLINE_xXUse of an investigational agent within 4 weeks of Day 1 visit.Xx_NEWLINE_xXOther investigational agent within 3 weeks prior to initiation of study therapyXx_NEWLINE_xXOther investigational agents currently or within 30 days prior to study enrollmentXx_NEWLINE_xXUse of any investigational drug within 4 weeksXx_NEWLINE_xXPatients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosingXx_NEWLINE_xXNo investigational drug within 4 weeks of starting study treatment.Xx_NEWLINE_xXConcurrent use of another investigational drug or device during, or within 3 weeks of starting study treatmentXx_NEWLINE_xXInvestigational agent received within 30 days prior to the first dose of study drug; if received any investigational agent prior to this time point, drug-related toxicities must have recovered to grade 2 or less prior to first dose of study drugXx_NEWLINE_xXUse of any investigational agent within 28 days prior to Baseline.Xx_NEWLINE_xXConcurrent treatment or treatment within 4 weeks of study entry with any other investigational agent or chemotherapy.Xx_NEWLINE_xXConcurrent treatment or treatment within 4 weeks of study entry with any other investigational agent or chemotherapy.Xx_NEWLINE_xXConcurrent use of another investigational drug or device during, or within 3 weeks of starting study treatmentXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXPatients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past 2 weeks prior to initiation of treatment with study drugsXx_NEWLINE_xXUse of any investigational drug or treatment within 4 weeks prior to enrollmentXx_NEWLINE_xXReceiving any other investigational agents or receipt of another investigational agent within 4 weeks of study entryXx_NEWLINE_xXPatients may not be receiving nor have received any other investigational agent =< 4 weeks prior to study registrationXx_NEWLINE_xXUse of any other type of investigational agent or treatment concurrently or within 28 days before the first dose of study treatmentXx_NEWLINE_xXHistory of receiving any investigational treatment within 28 days of study medication initiationXx_NEWLINE_xXReceipt of any investigational agent within 4 weeks prior to 1st doseXx_NEWLINE_xXReceived an investigational agent for another disease within 30 days prior to enrollmentXx_NEWLINE_xXPatients should not participate in any other therapeutic investigational study while taking part in this studyXx_NEWLINE_xXConcomitant use of any other investigational drugsXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXCurrently enrolled in (or completed within 30 days before study drug administration)another investigational drug study.Xx_NEWLINE_xXSubjects who have received any other investigational drug or agent within 28 days of first dose of TH-302Xx_NEWLINE_xXParticipation in any other investigational trial in which receipt of investigational drug or device occurred within 30 days prior to screening for this studyXx_NEWLINE_xXPatients who are receiving any other investigational agentXx_NEWLINE_xXTreatment with any other investigational agent, or participation in another investigational drug trial within 28 days prior to randomizationXx_NEWLINE_xXThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXBe currently enrolled in another investigational protocolXx_NEWLINE_xXPatients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of the first scheduled day of protocol treatment (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)Xx_NEWLINE_xXReceiving any other investigational agent considered as a treatment for the primary neoplasmXx_NEWLINE_xXAny investigational therapy in the past 30 daysXx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Biologic or investigational agent (anti-neoplastic): patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent >= 7 days prior to study enrollment \r\n* For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur, and discussed with the principal investigatorXx_NEWLINE_xXPatient is premenopausal (medical ovarian suppression is allowed); is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device.Xx_NEWLINE_xXInvestigational therapy less than one month prior to study entryXx_NEWLINE_xXThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXSimultaneous participation in any other study involving investigational drugs or having participated in a study less than 2 weeks prior to treatment in this studyXx_NEWLINE_xXAdministration of any investigational agents within 30 days before study entryXx_NEWLINE_xXParticipation in any investigational drug study within 28 days prior to ISF35 administration; (subject must have recovered from all acute effects of previously administered investigational agents)Xx_NEWLINE_xXTreatment with a non-approved or investigational drug or agent within 30 days before day 1 of trial treatmentXx_NEWLINE_xXCurrently enrolled in (or completed) another investigational drug study within 30 days prior to study drug administrationXx_NEWLINE_xXTreatment with any investigational agent within 3 weeks prior to first dose in this study.Xx_NEWLINE_xXThe subject has received any investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXTreatment with another investigational agent under the following conditions:Xx_NEWLINE_xXConcomitant treatment with another investigational agent while participating in this trial.Xx_NEWLINE_xXPatient has received other investigational drugs within 1 week before enrollment.Xx_NEWLINE_xXCurrent treatment with another investigational agent.Xx_NEWLINE_xXUse of any other investigational agent within 21 days before day 1.Xx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXReceived any other investigational therapy within 28 days of Day 1; orXx_NEWLINE_xXMore than 4 weeks from any investigational agent.Xx_NEWLINE_xXHave received treatment within 28 days of the initial dose of study drug with an investigational product or non-approved use of a drug or device (other than the study drug/device used in this study) or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.Xx_NEWLINE_xXPatients who are receiving any other investigational agents; if the patient received a previous investigational or other agent or treatment, a washout period of 4 weeks is requiredXx_NEWLINE_xXUse of any investigational agent within the last 28 daysXx_NEWLINE_xXParticipation in any investigational drug study within 4 weeks preceding the start of study treatmentXx_NEWLINE_xXSubjects who have participated in another investigational study within 30 days prior to surgery.Xx_NEWLINE_xXTreatment with an unapproved, investigational agent within 21 days of the first dose of study drugXx_NEWLINE_xXPrior participation in an investigational study (procedure or device) within 21 days of study day 1Xx_NEWLINE_xXinvestigational drug within 28 daysXx_NEWLINE_xXOngoing treatment with any other investigational therapyXx_NEWLINE_xXExposure to another investigational drug within 3 weeks prior to start of study treatment.Xx_NEWLINE_xXConcurrent treatment with an investigational agentXx_NEWLINE_xXTreatment with any investigational agent <=3 weeks prior to first dose of study treatmentXx_NEWLINE_xXReceiving other investigational agentXx_NEWLINE_xXPatients who have received any investigational drug within 28 days prior to Day 1 of study entry (an investigational drug is one for which there is no approved indication), or who are receiving concurrent treatment with other experimental drugs or anti-cancer therapyXx_NEWLINE_xXReceived an investigational agent <14 days prior to their first day of study drug administration. In addition, the first dose of AG-221 should not occur before a period ?5 half-lives of the investigational agent has elapsedXx_NEWLINE_xXPatients receiving other investigational agentXx_NEWLINE_xXAn investigational therapy.Xx_NEWLINE_xXPatients who are currently participating in or have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXPatients receiving any other current investigational therapeutic agent.Xx_NEWLINE_xXPrior exposure to an investigational agent or device within 30 days of signing the ICF. Of note, the subject may participate in observational studies;Xx_NEWLINE_xXAny other investigational drug/medical device within 3 weeks prior to the first doseXx_NEWLINE_xXTreatment with a non-approved or investigational drug within 30 days prior to day 1 of study treatmentXx_NEWLINE_xXTreatment with an unapproved, investigational therapeutic agent, immunotherapy or biological therapy within 21 days prior to the first dose of study drugXx_NEWLINE_xXExposure to any investigational agent within 30 days of date of randomization.Xx_NEWLINE_xXUse of other investigational drugsXx_NEWLINE_xXExposure to any investigational agent within 30 days of Randomization.Xx_NEWLINE_xXHas the subject received any investigational treatment within the past 30 days?Xx_NEWLINE_xXRecently received an investigational agent or deviceXx_NEWLINE_xXParticipation in concurrent study of an investigational agent or device.Xx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXFrench subjects: The French subject has participated in any study using an investigational study treatment(s) during the previous 30 days.Xx_NEWLINE_xXUse of an investigational therapeutic agent within 30 daysXx_NEWLINE_xXUse of investigational device or agents within 2 weeks of enrollment date.Xx_NEWLINE_xXConcurrent use of other investigational agentXx_NEWLINE_xXParticipating in another investigational drug or device trial that has not completed the follow-up periodXx_NEWLINE_xXInvestigational therapy or any other therapy =< 28 days before first study treatmentXx_NEWLINE_xXTreatment with any investigational productsXx_NEWLINE_xXIs participating in or has participated in other investigational interventional studies within the last 28 days prior to study treatmentXx_NEWLINE_xXParticipant has been exposed to an investigational product (IP) or investigational device in another clinical study within 4 weeks prior to IP administration, or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this studyXx_NEWLINE_xXSubject may not receive another investigational agent.Xx_NEWLINE_xXTreatment with another investigational drug or device within 28 days prior to Day 1Xx_NEWLINE_xXCurrently enrolled in another investigational device or drug studyXx_NEWLINE_xXTreatment with an investigational drug within 3 weeks prior to the first dose of study drugXx_NEWLINE_xXParticipated in any previous study of aprepitant or fosaprepitant, or taken an investigational drug within 4 weeks prior to study participationXx_NEWLINE_xXReceiving any other investigational agent that would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXInvestigational agents within 4 weeks of initial study treatment.Xx_NEWLINE_xXThe patient received treatment with another investigational agent within 14 days of screening.Xx_NEWLINE_xXAdministration of an investigational study treatment within 30 days preceding the first dose of study treatment(s) in this study.Xx_NEWLINE_xXMust be 28 days from the administration of any investigational agent or prior cytotoxic therapy with the following exceptions:Xx_NEWLINE_xXUse of an investigational agent within the past 30 daysXx_NEWLINE_xXAny investigational agent is acceptable if administered >= 30 days before registrationXx_NEWLINE_xXUse of any investigational agent within 28 days prior to start of CA-4948Xx_NEWLINE_xXCurrent participation in a treatment study or past participation in a study of an investigational agent within 4 weeks before the first dose of study treatmentXx_NEWLINE_xXCurrent participation in a treatment study or past participation in a study of an investigational agent within 4 weeks before the first dose of study treatmentXx_NEWLINE_xXPrior treatment with any investigational drug within the preceding 2 weeksXx_NEWLINE_xXPrior treatment with an investigational or approved agent for the purpose of inhibiting HER family membersXx_NEWLINE_xXReceiving any other investigational agentXx_NEWLINE_xXPatients may not have received an investigational agent within 4 weeks of starting this trialXx_NEWLINE_xXPatient who is concurrently using any other approved or investigational anti-neoplastic agentXx_NEWLINE_xXDonor must not be currently enrolled on another investigational agent study.Xx_NEWLINE_xXUse of investigational drug within 4 weeks of Day 1 Week 1 or current enrollment in an investigational drug or device studyXx_NEWLINE_xXTreatment with any other investigational agent within 28 days prior to randomizationXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXPatients may not use any of the following therapies during the study:\r\n* Any non-study anti-cancer agent (investigational or non-investigational)\r\n* Any other investigational agents\r\n* Any other (non-CA184024 related) CTLA-4 inhibitors or agonists\r\n* CD137 agonists\r\n* Immunosuppressive agents\r\n* Chronic systemic corticosteroids\r\n* Any non-oncology vaccine therapies used for the prevention of infectious diseases (for up to 30 days prior to or after any dose of study drug)Xx_NEWLINE_xXReceived treatment with an investigational agent within 4 weeks of study entry, or is actively participating in another interventional clinical study.Xx_NEWLINE_xXConcurrent investigational drugsXx_NEWLINE_xXSubject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s) or subject is receiving other investigational agents.Xx_NEWLINE_xXParticipation in an investigational therapeutic study within 14 days of initiation of study drug treatmentXx_NEWLINE_xXany investigational treatment within the past 30 daysXx_NEWLINE_xXNo treatment with any investigational agent within 14 days prior to registration for protocol therapy. NOTE: If treated with investigational agent within 14 days prior to registration, AE must be resolved back to baseline.Xx_NEWLINE_xXPrior treatment with any investigational drug within the preceding 4 weeksXx_NEWLINE_xXAny other investigational agent within 28 days of study entryXx_NEWLINE_xXThe participant is receiving any other investigational agent(s)Xx_NEWLINE_xXPatient received chemotherapy, biological or investigational agent ? 28 days prior to enrollment.Xx_NEWLINE_xXSubject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s), or subject is receiving other investigational agent(s)Xx_NEWLINE_xXParticipation in a study with an investigational drug from 4 weeks prior to study start until study endXx_NEWLINE_xXTreatment with a investigational drug within 28 days before Day 1 of trial treatment.Xx_NEWLINE_xXReceived an investigational agent for any indication within 30 days prior to first treatmentXx_NEWLINE_xXCurrently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to day 1Xx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for AL amyloidosisXx_NEWLINE_xXPatients receiving any other investigational agent(s)Xx_NEWLINE_xXAny antineoplastic agent (standard or investigational) within 2 weeks prior to starting trial treatmentXx_NEWLINE_xXAny treatment with investigational drugs within 30 days before the start of the studyXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXTherapy with any investigational products within 21 days before the first dose of study drugXx_NEWLINE_xXPatients who have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 14 days or 5 half -lives before registration or is currently enrolled in the treatment stage of an investigational study are not eligible; please contact PI for further details on wash-out period and eligibility of such patientsXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXConcurrent use of investigational therapeutic agentXx_NEWLINE_xXTreatment with another investigational agent currently or within 14 days prior to enrollment; patients may participate in other non-treatment studies concurrently if it will not interfere with participation in this studyXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXConcurrent use of investigational therapeutic agentXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXCurrently receiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXPatients may not be receiving any other investigational agentXx_NEWLINE_xXPatient is concurrently using other approved or investigational antineoplastic agentXx_NEWLINE_xXTreatment within the last 30 days with any investigational drugXx_NEWLINE_xXPatients who have received previous cytotoxic chemotherapy including an AC-T regimen or previous therapeutic radiation therapy for any reason in the last 5 years; because of possible limitations in bone marrow reserve, patients with such prior treatments are not appropriate candidates for this trial; patients who have had prior hormonal therapy (for instance, tamoxifen for prevention of breast cancer) are eligible; patients who have participated in a window study (treatment with an investigational agent prior to surgery for =< 2 weeks) are eligible but must have discontinued the investigational agent at least 14 days before enrollmentXx_NEWLINE_xXParticipating in any other investigational study for either drug or device which could influence collection of valid data under this studyXx_NEWLINE_xXUse of an investigational therapeutic within 30 daysXx_NEWLINE_xXUse of an investigational drug within 1 month prior to dosingXx_NEWLINE_xXPatient has received an investigational agent or cytotoxic chemotherapy (excluding hydroxyurea) within 7 days of study entryXx_NEWLINE_xXPatients who have received an investigational agent or have used an investigational device within 4 weeks of the first dose of study drugXx_NEWLINE_xXIs currently participating or has participated in a study with an investigational agent or using an investigational device within 4 weeks of the first dose of study therapyXx_NEWLINE_xXInvestigational therapy other than enzalutamide.Xx_NEWLINE_xXReceived an antineoplastic therapy or investigational agent after treatment with talazoparib in the originating protocol.Xx_NEWLINE_xXCurrently enrolled in another interventional clinical study or used any investigational drug or device within the past 28 days preceding informed consentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 2 weeks of the first dose of treatmentXx_NEWLINE_xX28 days from the administration of any investigational agentXx_NEWLINE_xXUse of an investigational agent for pain control concurrently or within the past 30 daysXx_NEWLINE_xXPatients who have received any investigational medication within 6 weeks of enrollment, or who are scheduled to receive an investigational drug during the course of the studyXx_NEWLINE_xXPatient who is participating in any investigational agent that is not Food and Drug Administration (FDA)-approvedXx_NEWLINE_xXSystemic therapy or investigational agent administered < 28 days prior to treatment with nintedanibXx_NEWLINE_xXParticipated in an investigational study for radiation dermatitis within 3 months of the screening visitXx_NEWLINE_xXAny prior investigational CMV vaccineXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXAny prior investigational CMV vaccineXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXAny prior investigational CMV vaccineXx_NEWLINE_xXConcurrent therapy with an investigational agentXx_NEWLINE_xXReceiving any other investigational agentXx_NEWLINE_xXReceiving any approved or investigational anti-cancer agent other than those provided for in this studyXx_NEWLINE_xXUse of an investigational agent for pain control concurrently or within the past 30 daysXx_NEWLINE_xXReceived any investigational agent =< 28 days before Treg infusionsXx_NEWLINE_xXConcurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)Xx_NEWLINE_xXParticipation in any investigational drug study within 4 weeks preceding the start of study treatmentXx_NEWLINE_xXPrior treatment with any investigational drug or device within 30 days prior to Randomization (within 2 weeks for investigational or approved immunotherapy) or currently participating in other investigational procedures;Xx_NEWLINE_xXParticipation in an interventional, investigational non-immunotherapy study within 2 weeks of the first dose of study treatment.Xx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXParticipation in any other investigational treatment within the 6 weeks prior to enrollment or concurrent with this study.Xx_NEWLINE_xXReceived any investigational treatment within 4 weeks prior to the start of study medication;Xx_NEWLINE_xXTreatment with an investigational anti-cancer study drug within 3 weeks prior to study drug administration dateXx_NEWLINE_xXInitiation of investigational agent =< 3 days after initiation of radiotherapyXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXPatients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosingXx_NEWLINE_xXSubjects who have received treatment with an investigational agent within 30 days of the projected first administration of Investigational Product (Day 0)Xx_NEWLINE_xXLess than 30 days since receipt of any investigational product or device. Investigational use/receipt of a medicinal product or device that has been approved by the country's local regulatory authority for any indication is permitted.Xx_NEWLINE_xXPatients must not have received any investigational agents within 30 days prior to commencing study treatmentXx_NEWLINE_xXUse of any investigational agent within 30 days of randomizationXx_NEWLINE_xXSubject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with this study.Xx_NEWLINE_xXParticipating in another investigational drug or device study in which patient has not completed the follow-up phase for the primary endpoint at least 30 days prior to enrollmentXx_NEWLINE_xXTreatment with any investigational agent within 30 days prior to registration for protocol therapyXx_NEWLINE_xXConcurrent participation in another study involving investigational drugs or investigational medical devicesXx_NEWLINE_xXUse of investigational agent within 30 days of study entryXx_NEWLINE_xXPatients who have received any investigational medication within 6 weeks of enrollment, or who are scheduled to receive an investigational drug during the course of the studyXx_NEWLINE_xXAdministration of any investigational agent =< 30 days prior to pre-registrationXx_NEWLINE_xXPatient is using or plans to use an investigational agent for the prevention or treatment of VOD.Xx_NEWLINE_xXAny investigational drug being administered during the studyXx_NEWLINE_xXInvestigational Drugs: Subjects who are currently receiving another investigational drug are excluded from participation.Xx_NEWLINE_xXTreatment with any investigational drug or investigational biologic within 30 days of initiating study treatment or during the studyXx_NEWLINE_xXConcurrent treatment with other investigational agentXx_NEWLINE_xXPrior treatment with a JAK inhibitor or with an investigational agent, device, or procedure within 21 days of enrollment.Xx_NEWLINE_xXTreatment with any investigational drug or investigational biologic within 30 days of initiating study treatment or during the studyXx_NEWLINE_xXPatient aged < 6 years who received any investigational drug (defined as a medication with no marketing authorization granted for any age class and any indication) within 90 days prior to Day 1, or patient aged 6 years who received any investigational drug within 30 days prior to Day 1 or is expected to receive investigational drugs prior to study completion.Xx_NEWLINE_xXPatient who is receiving investigational agent(s) as part of another clinical study at the time of screening or who anticipates receiving investigational agent(s) during their scheduled radiotherapy and concomitant daily temozolomide therapy (e.g. through the BMX001, MRZ 112, and BMX 209-548 studies)Xx_NEWLINE_xXReceived any investigational agent within the 14 days before the start of study treatment (1st dose of ALT-803)Xx_NEWLINE_xXPatients who have received an investigational drug within 30 days of enrollment in studyXx_NEWLINE_xXEnrollment on an interventional investigational studyXx_NEWLINE_xXUse of an investigational drug in the 3 months prior to screening and must agree to not participate in any drug or device study while enrolled in this studyXx_NEWLINE_xXPatients who are participating in another experimental protocol during the study period (last intake of investigational drug within 6 months prior to first study drug injection)Xx_NEWLINE_xXHas received an investigational study agent within the previous 30 days, or is currently participating in or scheduled to participate in any other clinical study with an investigational agent during the 12-week study periodXx_NEWLINE_xXExposure to any investigational agent (defined as any agent not approved by the Food and Drug Administration [FDA]) within 30 days prior to the Screening VisitXx_NEWLINE_xXCurrently enrolled on an interventional investigational studyXx_NEWLINE_xXUse of non-study investigational agent(s) =< 3 months prior to randomizationXx_NEWLINE_xXInvestigational Drugs: Subjects who are currently receiving another investigational drug are excluded from participation.Xx_NEWLINE_xXInvestigational Drugs: Subjects who are currently receiving another investigational drug are excluded from participation.Xx_NEWLINE_xXReceiving any other investigational agent =< 3 months prior to registration/randomization, except innocuous agents with no known interaction with the study agent (e.g., standard dose multivitamins or topical agents for limited skin conditions)Xx_NEWLINE_xXTreatment with any local or systemic anti-neoplastic therapy or any other investigational agent in the 4 weeks prior to study drug administrationXx_NEWLINE_xXPatients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosingXx_NEWLINE_xXInvestigational Drugs: Patients who are currently receiving another investigational drug are excluded from participation.Xx_NEWLINE_xXPatients should have been off other investigational therapy for one month prior to entry in this studyXx_NEWLINE_xXHas ever participated in a previous study of aprepitant or fosaprepitant or has taken an investigational drug with the last 4 weeks.Xx_NEWLINE_xXHas participated in a study with an unapproved investigational compound (monoclonal antibodies are excepted) or device within 28 days of the first dose of study drugXx_NEWLINE_xXHas, is, or is planning (during the study) to participate in any study involving administration of a CMV vaccine or another CMV investigational agentXx_NEWLINE_xXConcurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. NOTE: Subjects enrolled in this study may also be eligible for a four-year gynaecological follow-up of the HPV-015 study, in which no investigational product will be administered. Subjects will be invited to the gynaecological follow-up study if either of the following applies:Xx_NEWLINE_xXThe patient has participated in another investigational drug study within 30 days of scheduled surgeryXx_NEWLINE_xXReceived an investigational agent in another investigational drug or vaccine trial within 30 days prior to surgeryXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXNot receiving any other investigational agents (i.e., unlabeled drugs or drugs under an investigational new drug [IND] for initial efficacy investigations)Xx_NEWLINE_xXNot receiving any other investigational agents (i.e., unlabeled drugs or drugs under an investigational new drug (IND) for initial efficacy investigationsXx_NEWLINE_xXConcomitant investigational therapyXx_NEWLINE_xXIs currently participating and receiving study therapy for his/her advanced melanoma or has participated in a study of an investigational agent and received study therapy in the advanced melanoma settingXx_NEWLINE_xXConcomitant investigational therapyXx_NEWLINE_xXHEALTHY VOLUNTEER: Participation in an investigational drug study within the period starting 1 month before study drug administrationXx_NEWLINE_xXPatient has been treated with an investigational drug, investigational biologic, or investigational therapeutic device within 14 days prior to study radiotracer administrationXx_NEWLINE_xXTreatment with any investigational drug, device or biologic agent within 30 days prior to administration of [18F]-ML-10.Xx_NEWLINE_xXCurrent enrollment in an investigational drug or device study, or participation in such a study within 30 days of first administration of the hormonal agentXx_NEWLINE_xXUse of any other investigational product or device within 30 days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessmentsXx_NEWLINE_xXAgrees not to receive any other investigational product or therapy while participating in this study.Xx_NEWLINE_xXReceived other investigational products or therapy in the 60 days prior to study drug administration.Xx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXIs currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.Xx_NEWLINE_xXSubjects must not receive concurrent or prior use of an immunosuppressive agent within 14 days of the first dose of investigational agent, with the following exceptions and notes:Xx_NEWLINE_xXSubjects must not have received another investigational agent within the shorter of 4 weeks or 5 half-lives before the first dose of investigational agent.Xx_NEWLINE_xXPrior exposure to azacitidine, decitabine or investigational hypomethylating agentXx_NEWLINE_xXTreatment with a prior investigational agent within 30 days of planned instillation of NanoPac®, with the exception of subjects participating in poly (ADP-ribose) polymerase (PARP) inhibitor trials. These subjects must discontinue the investigational agent prior to surgeryXx_NEWLINE_xX2 weeks since any oral anti-neoplastic or oral investigational agentXx_NEWLINE_xXCurrently participating and receiving study therapy (except lenvatinib for patients in cohort 2) or has participated in a study of an investigational agent and received study therapy within 4 weeks prior to registrationXx_NEWLINE_xXPlanned participation in another study of an investigational agent or investigational device or use of a therapeutic device intended for therapy of gliomaXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatmentXx_NEWLINE_xXCurrently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study.Xx_NEWLINE_xXHas received investigational drugs suspected to cause peripheral neuropathy; no concurrent investigational drugs may be usedXx_NEWLINE_xXuse of any investigational drug within 4 weeks of dosing (unless a longer time period is required by local regulations or the investigational agent)Xx_NEWLINE_xXThe subject has participated in another investigational drug study within 30 days of scheduled surgery.Xx_NEWLINE_xXPatient is participating in any other investigational drug or device studyXx_NEWLINE_xXPatients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of the first scheduled day of protocol treatment* (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)Xx_NEWLINE_xXReceiving any other investigational agent that would be considered as a treatment for the lymphoma; NOTE: rituximab maintenance and patients participating on Mayo Clinic vitamin D study are allowedXx_NEWLINE_xXReceived an investigational agent within 30 days prior to enrollmentXx_NEWLINE_xXUse of an investigational agent within 4 weeks of enrollmentXx_NEWLINE_xXMay have received treatment with an investigational product.Xx_NEWLINE_xXTreatment with any investigational product within 30 days before the first infusion.Xx_NEWLINE_xXInvestigational drugs: must not be receiving other investigational (from other studies) drugs at time of enrollment and must not be planning to take other investigational drugs during DLT periodXx_NEWLINE_xXThe patient has received an investigational drug within 30 days of the first dose of study drug.Xx_NEWLINE_xXThe patient participated in another clinical investigation within 30 days of enrollment or is receiving another investigational agent.Xx_NEWLINE_xXReceipt of an investigational drug or device within 30 days of enrollment.Xx_NEWLINE_xXPatients who have been treated with chemotherapy, with biological therapy or other investigational agent must have discontinued the treatment at least 2 weeks (14 days) prior to starting the study drug on Study Day -Xx_NEWLINE_xXReceived an investigational agent in another investigational drug or vaccine trial within 30 days prior to surgeryXx_NEWLINE_xXOther investigational drugsXx_NEWLINE_xXThe participant is receiving any other investigational agent(s).Xx_NEWLINE_xXThe participant is receiving any other investigational agent(s).Xx_NEWLINE_xXNo investigational agent within 4 weeks prior to first dose of study drugXx_NEWLINE_xXCurrently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks prior to enrollment .Xx_NEWLINE_xXIs currently participating in a clinical study and receiving an investigational agent and/or using an investigational device, or has participated in a clinical study and received an investigational agent and/or used an investigational device within 4 weeks prior to randomization.Xx_NEWLINE_xXCurrently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.Xx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent and is currently receiving study therapy or has participated in a study of an investigational agent and has received study therapy or used an investigational device within 4 weeks of the first dose of study drug.Xx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xX